Fusion Antibodies PLC (FAB) — Capital Reinvestment Ratio
Fusion Antibodies PLC (FAB) has a Capital Reinvestment Ratio of 0.39x as of March 2022, meaning it reinvests 0% of its operating cash flow (GBX174.00K) in capital expenditures (GBX67.00K). See how leveraged is Fusion Antibodies PLC's balance sheet to measure how much of total assets are equity-financed.
Capital Reinvestment Ratio
Operating Cash Flow
Capital Expenditures
Data as of
Fusion Antibodies PLC Capital Reinvestment Ratio (2016–2018)
This chart tracks Fusion Antibodies PLC's Capital Reinvestment Ratio across 2 annual periods. Check Fusion Antibodies PLC (FAB) total reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Annual Capital Reinvestment Ratio for Fusion Antibodies PLC (2016–2018)
Year-by-year Capital Reinvestment Ratio for Fusion Antibodies PLC from 2016 to 2018. For live market cap and broader valuation context, see FAB company net worth.
| Year | Reinvestment Ratio | Operating CF (GBX) | Capital Expenditures | YoY Change |
|---|---|---|---|---|
| 2018 | 5.76x | GBX77.19K | GBX444.60K | ▲ +5481.8% |
| 2016 | 0.10x | GBX346.57K | GBX35.76K | — |